SCHEDULE: Glazer Capital Reports Stake in Drugs Made in America

Glazer Capital, LLC and Paul J. Glazer have reported beneficial ownership of 4.12% of Drugs Made in America Acquisition Corp.'s ordinary shares.

Summary

• Glazer Capital, LLC, an investment manager, and its Managing Member, Paul J. Glazer, have filed a Schedule 13G.
• This filing indicates their beneficial ownership of 999,899 ordinary shares of Drugs Made in America Acquisition Corp.
• This ownership represents 4.12% of the class of securities.
• The filing is an amendment (Amendment No. 1) and the event date requiring the filing is June 30, 2026.
• Both Glazer Capital, LLC and Paul J. Glazer are identified as Reporting Persons.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• The filing clearly discloses a significant ownership stake, providing transparency to the market.
• The reporting persons are investment professionals, suggesting their investment is based on fundamental analysis.

Negatives

• No new financial or operational performance data is provided in this filing.
• The filing does not offer insights into the strategic direction or future prospects of the company.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Glazer Capital's interest in Drugs Made in America Acquisition Corp., but without further context on the company's specific sector or performance, its broader industry implications are limited.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes can influence investor sentiment and trading activity.
• Management: The filing signals that a substantial institutional investor is monitoring the company's performance and strategy.

Next Steps

• Continue to monitor future filings from Glazer Capital and Drugs Made in America Acquisition Corp. for any changes in ownership or company performance.

Key Dates

Keywords

beneficial ownership, Schedule 13G, investment manager, ordinary shares, acquisition corp, Glazer Capital